

*This report contains the collective views of an international group of experts and does not necessarily represent the decisions or the stated policy of the World Health Organization*

**WHO Technical Report Series**

**945**

---

# **THE SCIENTIFIC BASIS OF TOBACCO PRODUCT REGULATION**

---

Report of a WHO Study Group



**World Health  
Organization**

---

The scientific basis of tobacco product regulation : report of a WHO study group.

(WHO technical report series ; no. 945)

1.Tobacco - adverse effects. 2.Tobacco industry - legislation. 3.Tobacco use disorder. I.World Health Organization. II.WHO Tobacco Free Initiative. III.Series.

ISBN 978 92 4 120945 8

(NLM classification: QV 137)

ISSN 0512-3054

**© World Health Organization 2007**

All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [bookorders@who.int](mailto:bookorders@who.int)). Requests for permission to reproduce or translate WHO publications –whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [permissions@who.int](mailto:permissions@who.int)).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

This publication contains the collective views of an international group of experts and does not necessarily represent the decisions or the stated policy of the World Health Organization.

Typeset in India

Printed in Switzerland

# Contents

<b>1. Introduction</b>	<b>1</b>
1.1 Background	2
References	5
<b>2. Contents and design features of tobacco products: their relationship to dependence potential and consumer appeal</b>	<b>7</b>
2.1 Background	7
2.2 Terminology	8
2.3 Relationship between dependence potential and harm	10
2.4 Effect of contents and designs on dependence potential	11
2.4.1 Nicotine dose level	11
2.4.2 Other contents	11
2.4.3 Modifying nicotine delivery speed and efficiency by pH and free nicotine control	11
2.5 Regulatory implications and challenges	13
2.5.1 Personal and local vendor-made products	15
2.5.2 Nicotine levels	15
2.5.3 Assessing and regulating dependence potential	15
2.6 Conclusions	16
2.7 Research needs	17
2.8 Regulatory recommendations	18
References	20
<b>3. Candy-flavoured tobacco products: research needs and regulatory recommendations</b>	<b>25</b>
3.1 Introduction	25
3.2 Purpose of the recommendations	25
3.3 Background	26
3.4 Description of flavoured tobacco products	28
3.4.1 Flavoured brands	28
3.4.2 Flavour application	34
3.5 Regional and global patterns of flavoured tobacco product use	35
3.6 Impact on public health	37
3.7 Science base and conclusions	38
3.8 Research needs	38
3.9 Regulatory recommendations	39
References	40
<b>4. Biomarkers of tobacco exposure and of tobacco smoke-induced health effects</b>	<b>43</b>
4.1 Introduction	43
4.2 Background	43
4.3 Biomarkers: definition and description	45
4.4 Measuring exposure	45
4.5 Measuring injury and disease	47
4.6 Existing evidence on biomarkers	47

4.7	Specific biomarkers	48
4.7.1	Tobacco alkaloids	49
4.7.2	Minor tobacco alkaloids	51
4.7.3	Other particulate phase components	52
4.7.4	Gas phase components	53
4.7.5	DNA and protein adducts	54
4.7.6	Mutagenic activity of the urine	56
4.8	Measuring biological changes	56
4.8.1	Assessing oxidative stress	58
4.8.2	Measures of inflammation	58
4.8.3	Measures of endothelial dysfunction	59
4.8.4	Measures of clotting	59
4.8.5	Insulin resistance	60
4.8.6	Circulating endothelial precursor cells	60
4.8.7	Femoral and internal carotid artery intima-media thickness	60
4.8.8	Sister chromatid exchanges in peripheral lymphocytes	60
4.9	Summary of existing biomarkers	60
4.10	Recommended uses for biomarkers of exposure and effect	64
4.10.1	Improving the accuracy of the definition of current tobacco use status	64
4.10.2	Evaluating the intensity of exposure to specific constituents	66
4.10.3	Evaluating the intensity of exposure as a proxy for total tobacco exposure	68
4.10.4	Measuring reduced injury or harm	69
4.11	Summary of biomarker recommendations	70
	References	72
5.	<b>Setting maximum limits for toxic constituents in cigarette smoke</b>	77
5.1	Introduction	77
5.2	Regulatory strategy	80
5.3	Selection of the machine-testing method	83
5.4	Criteria for selecting constituents for regulating maximum limits	85
5.5	Specific regulatory recommendations for TSNAs	89
5.6	Interpretation of the maximum limit values	92
5.7	Communication of the results of the testing to the public	92
5.8	Methods for measuring nitrosamines	93
5.9	Considerations for modified cigarettes and potential reduced exposure products	94
5.10	Future directions	95
	References	96
6.	<b>Overall recommendations</b>	99
6.1	Contents and design features of tobacco products: their relationship to dependence potential and consumer appeal	99
6.2	Candy-flavoured tobacco products: research needs and regulatory recommendations	100

6.3	Biomarkers of tobacco exposure and of tobacco smoke-induced health effects	101
6.4	Setting maximum limits for toxic constituents in cigarette smoke	102
	<b>Acknowledgements</b>	105
	<b>Annex 1</b>	107
	Reports and other documents arising from meetings of the WHO Scientific Advisory Committee on Tobacco Product Regulation (SACTob)	107
	Statement of principles guiding the evaluation of new or modified tobacco products (2003)	107
	Recommendation on nicotine and its regulation in tobacco and non-tobacco products (2002)	107
	Recommendation on tobacco product ingredients and emissions (2003)	108
	SACTob recommendations on health claims derived from ISO/FTC method to measure cigarette yield (2003)	108
	Recommendation on smokeless tobacco products (2003)	109
	<b>Annex 2</b>	111
	Reports and other documents arising from meetings of the WHO Study Group on Tobacco Product Regulation (TobReg)	111
	Guiding principles for the development of tobacco product research and testing capacity and proposed protocols for the initiation of tobacco product testing: recommendation 1 (2004)	111
	Best practices in tobacco control: regulation of tobacco products: Canada report (2005)	111
	Advisory note: waterpipe tobacco smoking: health effects, research needs and recommended actions by regulators (2005)	112



# WHO Study Group on Tobacco Product Regulation

Kobe, Japan, 28–30 June 2006

## Members

Dr D.L. Ashley, Chief, Emergency Response and Air Toxicants Branch, Centers for Disease Control and Prevention, Atlanta, GA, USA

Dr D. Burns, Professor of Family and Preventive Medicine, University of California, San Diego, School of Medicine, CA, USA

Dr M. Djordjevic, Program Director, National Cancer Institute, Division of Cancer Control and Population Sciences, Tobacco Control Research Branch, Bethesda, MD, USA

Dr E. Dybing, Chair of the WHO Study Group on Tobacco Product Regulation; Director, Division of Environmental Medicine, Norwegian Institute of Public Health, Oslo, Norway

Dr N. Gray, Scientist, International Agency for Research on Cancer, Lyon, France

Dr S.K. Hammond, Professor of Environmental Health Sciences, University of California, Berkeley, School of Public Health, Berkeley, CA, USA

Dr J. Henningfield, Professor (Adjunct), Behavioral Biology, Johns Hopkins University School of Medicine; Vice President, Research and Health Policy, Pinney Associates, Bethesda, MD, USA

Dr M. Jarvis, Principal Scientist, Cancer Research UK, Health Behaviour Unit, Royal Free and University College London Medical School, London, England

Dr K.S. Reddy, Professor of Cardiology, All India Institute of Medical Sciences, Delhi, India

Dr C. Robertson, Senior Associate Dean for Faculty and Academic Affairs, School of Engineering, Stanford University, CA, USA

Dr G. Zaatari, Professor, Department of Pathology and Laboratory Medicine, American University of Beirut, Beirut, Lebanon

### **Secretariat**

Dr D.W. Bettcher, Coordinator, Framework Convention on Tobacco Control, WHO, Geneva, Switzerland

Dr Y. Mochizuki, Director, Tobacco Free Initiative, WHO, Geneva, Switzerland

Ms E. Tecson, Administrative Assistant, Tobacco Free Initiative, WHO, Geneva, Switzerland

Ms G. Vestal, Legal Officer & Scientist, Framework Convention on Tobacco Control, Tobacco Free Initiative, WHO, Geneva, Switzerland

已结束，完整报告链接和二维码如下：

[www.yunbaogao.cn/report/index/report?reportId=5\\_29585](http://www.yunbaogao.cn/report/index/report?reportId=5_29585)

